Rosso 1988.

Methods	Randomized multi‐center trial Eligible patients Cytologically or histologically confirmed NSCLC Stage III considered unresectable or stage IV ECOG PS: 0 to 2 ≤ 75 years of age No previous chemotherapy Exclusion criteria Brain metastasis
Participants	E arm: 113 participants (ITT population) ‐ median age (range): not reported/56 participants > 60 years of age/elderly population not reported EP arm: 103 participants (ITT population) ‐ median age (range): not reported/59 participants > 60 years of age/elderly population not reported
Interventions	E arm: etoposide 120 mg/m2 i.v. infusion on days 1, 2, and 3, every 3 weeks EP am: cisplatin 60 mg/m2 on days 1 and 2 plus etoposide 120 mg/m2 i.v. infusion on days 1, 2, and 3, every 3 weeks for maximum of 6 cycles
Outcomes	Neither primary nor secondary outcomes reported
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Patients were randomised to be treated...." No further information no random sequence generation
Allocation concealment (selection bias)	Unclear risk	No information on allocation concealment
Blinding of outcome assessment (detection bias) OS and 1y OS rate outcome	Unclear risk	No information on blinding
Blinding of outcome assessment (detection bias) Other outcomes	High risk	No information on blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	"Of 216 patients accrued into the study, 23 were not evaluable..."
Selective reporting (reporting bias)	Low risk	No evidence of reporting bias
Other bias	Unclear risk	No separate elderly subgroup analysis